Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 10, 2001, Pages 1593-1601

  Hawkey, C J ^a   Laine, L ^b   Harper, S E ^c   Quan, H U I ^c   Bolognese, J A ^c   Mortensen, E ^c  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DOUBLE BLIND PROCEDURE; DRUG USE; ENDOSCOPY; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX; SMOKING; ULCER;

AGED; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; ENDOSCOPY, GASTROINTESTINAL; FEMALE; HUMANS; IBUPROFEN; ISOENZYMES; LACTONES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; OSTEOARTHRITIS; PEPTIC ULCER HEMORRHAGE; PEPTIC ULCER PERFORATION; PROSPECTIVE STUDIES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RISK FACTORS; STOMACH ULCER; SULFONES;

EID: 0034789554     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.01007.x     Document Type: Article

References (24)

1. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes
2. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
3. Pharmacological and biochemical demonstration of the role of cyclooxygenase (COX)-2 in inflammation and pain
4. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissue. Effects of interleukin-1 beta, phorbol ester, and corticosteroids
5. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
6. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
7. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26-week controlled clinical trial
8. MK-0966. A specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6-week controlled trial
9. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
10. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
11. A randomized, double-blinded comparison of the effect of rofecoxib (a drug specifically inhibiting COX-2), ibuprofen, or placebo on the gastroduodenal mucosa of osteoarthritis patients
12. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats
13. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice
14. Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: A topographic study of H. pylori density and distribution
15. Simultaneous visualization of Helicobacter pylori and gastric morphology: A new stain
16. Gastrointestinal side effects of non-steroidal anti-inflammatory drugs
17. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter eradication for lesion prevention
18. Omeprazole compared with misoprostol for ulcers associated with non-steroidal antiinflammatory drugs
19. A comparison of omeprazole and ranitidine for treating and preventing ulcers associated with non-steroidal anti-inflammatory drugs. Acid supression trial: Ranitidine versus omeprazole for NSAID-associated ulcer treatment (ASTRONAUT) study group
20. Personal review: Helicobacter pylori, NSAIDs and cognitive dissonance
21. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients
22. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs
23. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analaysis
24. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons